<p>如果你希望为你的投资组合增加增长，生物科技股票可以是一个很好的选择。这些公司的实验室正在进行令人兴奋的研究，在某些情况下，改变游戏规则的治疗候选药物正接近重要的里程碑，甚至已经成功上市。作为这些公司的投资者，你可以在它们发布积极的临床试验消息、获得监管批准或开始产生产品收入时受益。</p>
<p>华尔街目前认为有两个候选公司极具吸引力，预计在未来 12 个月内潜在收益超过 80% 和 200%。其中一家公司专注于高增长的减肥药领域，另一家公司则通过赢得全球首个基于 CRISPR 基因编辑的产品批准展现了其实力。让我们来看看这两只生物科技股票，在它们飙升之前买入。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjIzNDAvZ2V0dHlpbWFnZXMtNDY4Njc5MTc2LmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjIzNDAvZ2V0dHlpbWFnZXMtNDY4Njc5MTc2LmpwZyZ3PTcwMA"/></p>
<p>图片来源：Getty Images。</p>
<h2>1. Viking Therapeutics</h2>
<p><strong>Viking Therapeutics</strong>(VKTX -0.88%) 在去年初因其减肥候选药物 VK2735 的二期试验报告强劲数据而大幅上涨，但自那以来，股价已回落，接近数据公告前的水平。</p>
<p>此后，公司继续推进 VK2735 的注射剂和片剂版本，这类药物的需求依然很高——这两个原因使得人们相信 Viking 有潜力再次腾飞。而催化剂可能就在眼前。</p>
<p>该药物的作用机制类似于 <strong>Eli Lilly</strong> 的畅销药物 tirzepatide，后者以 Mounjaro 和 Zepbound 的名称销售。这些药物与消化相关的激素相互作用，帮助人们快速安全地减轻体重。Viking 预计将在第二季度开始注射剂 VK2735 的三期试验，并预计在下半年发布片剂版本的二期试验数据。任何数据公告都可能导致股价大幅波动，因为市场上仍有足够的空间让新公司进入减肥药市场——预计在几年内该市场将接近 1000 亿美元。</p>
<p>华尔街对 Viking 的前景持乐观态度，平均价格预测显示股价将从目前水平上涨约 240%。当然，Viking 在很大程度上依赖于这些试验的结果，因此存在一定风险——但数据表现强劲，因此增长型投资者可能希望现在就投资 Viking，以便在未来获得丰厚回报。</p>
<h2>2. CRISPR Therapeutics</h2>
<p><strong>CRISPR Therapeutics</strong>(CRSP -0.41%) 的股票在其首个产品批准前的一年内大幅上涨。但自去年推出针对血液疾病的基因编辑治疗 Casgevy 以来，股价一直在下滑。有时，投资者在公司获得批准或推出产品之前就会购买股票，然后在好消息发布后锁定收益——我认为这就是这里发生的情况。</p>
<p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/c16cd5aa93b15d7cdb43126635ac1fe3.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/c16cd5aa93b15d7cdb43126635ac1fe3.png"/></p>
<p>CRSP 数据来源于 YCharts</p>
<p>但这为我们提供了一个以非常好的价格进入一家有前景的公司的机会，该公司可能在未来发布令人振奋的消息。作为一种基因编辑治疗，Casgevy 的推出需要比片剂或注射剂更长的时间，因为它涉及几个步骤，持续数月。公司最近表示，今年新患者的启动应该会 “显著” 增加——因此对未来收入增长持乐观态度是有理由的。</p>
<p>CRISPR Therapeutics 最近还报告了针对高胆固醇问题的基因编辑候选药物的积极一期数据。公司预计很快将发布针对高脂蛋白 (a) 患者的候选药物的一期试验数据——这是一种心血管事件的风险因素。如果这些候选药物成功上市，可能会为 CRISPR Therapeutics 带来巨大的市场，同时，任何潜在的积极消息都可能推动股价上涨。</p>
<p>公司还预计今年将有其他针对肿瘤和自身免疫疾病的候选药物的试验更新——因此这家生物科技公司的日程表充满了潜在的催化剂。</p>
<p>华尔街的平均价格预测显示 CRISPR Therapeutics 的股价将从目前价格上涨 84%——如果临床试验顺利进行，Casgevy 开始显示收入增长，现在可能是增长型投资者的黄金买入机会。</p>

Viking治疗

CRISPR治疗

<p>两只生物科技股票，Viking Therapeutics 和 CRISPR Therapeutics，被认为是潜在的高增长投资。Viking Therapeutics 专注于减肥药物，预计其 VK2735 药物在临床试验中推进时，股价将上涨 240%。CRISPR Therapeutics 的基因编辑治疗 Casgevy 预计将上涨 84%，因为它预期将实现显著的收入增长和积极的试验结果。这两家公司为希望利用即将到来的临床里程碑和市场需求的投资者提供了机会</p>

<p>If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue.</p>
<div class="lb-trans"><p>如果你希望为你的投资组合增加增长，生物科技股票可以是一个很好的选择。这些公司的实验室正在进行令人兴奋的研究，在某些情况下，改变游戏规则的治疗候选药物正接近重要的里程碑，甚至已经成功上市。作为这些公司的投资者，你可以在它们发布积极的临床试验消息、获得监管批准或开始产生产品收入时受益。</p>
</div><p>Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket.</p>
<div class="lb-trans"><p>华尔街目前认为有两个候选公司极具吸引力，预计在未来 12 个月内潜在收益超过 80% 和 200%。其中一家公司专注于高增长的减肥药领域，另一家公司则通过赢得全球首个基于 CRISPR 基因编辑的产品批准展现了其实力。让我们来看看这两只生物科技股票，在它们飙升之前买入。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjIzNDAvZ2V0dHlpbWFnZXMtNDY4Njc5MTc2LmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F822340%2Fgettyimages-468679176.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>1. Viking Therapeutics</h2>
<div class="lb-trans"><h2>1. Viking Therapeutics</h2>
</div><p><strong>Viking Therapeutics</strong>(VKTX -0.88%) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement.</p>
<div class="lb-trans"><p><strong>Viking Therapeutics</strong>(VKTX -0.88%) 在去年初因其减肥候选药物 VK2735 的二期试验报告强劲数据而大幅上涨，但自那以来，股价已回落，接近数据公告前的水平。</p>
</div><p>Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon.</p>
<div class="lb-trans"><p>此后，公司继续推进 VK2735 的注射剂和片剂版本，这类药物的需求依然很高——这两个原因使得人们相信 Viking 有潜力再次腾飞。而催化剂可能就在眼前。</p>
</div><p>The drug works in a manner similar to <strong>Eli Lilly</strong>'s blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years.</p>
<div class="lb-trans"><p>该药物的作用机制类似于 <strong>Eli Lilly</strong> 的畅销药物 tirzepatide，后者以 Mounjaro 和 Zepbound 的名称销售。这些药物与消化相关的激素相互作用，帮助人们快速安全地减轻体重。Viking 预计将在第二季度开始注射剂 VK2735 的三期试验，并预计在下半年发布片剂版本的二期试验数据。任何数据公告都可能导致股价大幅波动，因为市场上仍有足够的空间让新公司进入减肥药市场——预计在几年内该市场将接近 1000 亿美元。</p>
</div><p>Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later.</p>
<div class="lb-trans"><p>华尔街对 Viking 的前景持乐观态度，平均价格预测显示股价将从目前水平上涨约 240%。当然，Viking 在很大程度上依赖于这些试验的结果，因此存在一定风险——但数据表现强劲，因此增长型投资者可能希望现在就投资 Viking，以便在未来获得丰厚回报。</p>
</div><h2>2. CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>2. CRISPR Therapeutics</h2>
</div><p><strong>CRISPR Therapeutics</strong>(CRSP -0.41%) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here.</p>
<div class="lb-trans"><p><strong>CRISPR Therapeutics</strong>(CRSP -0.41%) 的股票在其首个产品批准前的一年内大幅上涨。但自去年推出针对血液疾病的基因编辑治疗 Casgevy 以来，股价一直在下滑。有时，投资者在公司获得批准或推出产品之前就会购买股票，然后在好消息发布后锁定收益——我认为这就是这里发生的情况。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/c16cd5aa93b15d7cdb43126635ac1fe3.png" alt="" original-src="https://media.ycharts.com/charts/c16cd5aa93b15d7cdb43126635ac1fe3.png"/></p>
<p>CRSP data by YCharts</p>
<div class="lb-trans"><p>CRSP 数据来源于 YCharts</p>
</div><p>But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase &#34;significantly&#34; this year -- so there's reason to be optimistic about revenue growth ahead.</p>
<div class="lb-trans"><p>但这为我们提供了一个以非常好的价格进入一家有前景的公司的机会，该公司可能在未来发布令人振奋的消息。作为一种基因编辑治疗，Casgevy 的推出需要比片剂或注射剂更长的时间，因为它涉及几个步骤，持续数月。公司最近表示，今年新患者的启动应该会 “显著” 增加——因此对未来收入增长持乐观态度是有理由的。</p>
</div><p>CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock.</p>
<div class="lb-trans"><p>CRISPR Therapeutics 最近还报告了针对高胆固醇问题的基因编辑候选药物的积极一期数据。公司预计很快将发布针对高脂蛋白 (a) 患者的候选药物的一期试验数据——这是一种心血管事件的风险因素。如果这些候选药物成功上市，可能会为 CRISPR Therapeutics 带来巨大的市场，同时，任何潜在的积极消息都可能推动股价上涨。</p>
</div><p>The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts.</p>
<div class="lb-trans"><p>公司还预计今年将有其他针对肿瘤和自身免疫疾病的候选药物的试验更新——因此这家生物科技公司的日程表充满了潜在的催化剂。</p>
</div><p>Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors.</p>
<div class="lb-trans"><p>华尔街的平均价格预测显示 CRISPR Therapeutics 的股价将从目前价格上涨 84%——如果临床试验顺利进行，Casgevy 开始显示收入增长，现在可能是增长型投资者的黄金买入机会。</p>
</div>

根据某些华尔街分析师的预测，有两只生物科技股票在预计将分别上涨 84% 和 240% 之前值得购买